Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02100514 · ClinicalTrials.gov registry record · Phase 3
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 746
- Enrollment target
NCT02100514 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 746 participants.
The verdict
NCT02100514, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 746 participants
- Enrollment target
Study Summary
This study is a multicenter, double-blind, randomized study to access the efficacy, safety and tolerability of Bococizumab (PF-04950615; RN316) in subjects with hyperlipidemia receiving background statin therapy.
Interventions
- OTHER Placebo
- DRUG Bococizumab (PF-04950615; RN316)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 746 participants |
| Start Date | 2014-10-28 |
| Est. Completion | 2017-07-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02100514
The ClinicalTrials.gov registry entry for NCT02100514 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 746 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02100514 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02100514 about?
NCT02100514 is a clinical study titled "Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events". This study is a multicenter, double-blind, randomized study to access the efficacy, safety and tolerability of Bococizumab (PF-04950615; RN316) in subjects with hyperlipidemia receiving background statin therapy.
What is the current status of trial NCT02100514?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 746 participants. The study started on 2014-10-28. Estimated completion is 2017-07-10.
What interventions are being tested in trial NCT02100514?
The interventions under investigation include: Placebo (OTHER), Bococizumab (PF-04950615; RN316) (DRUG).
Who is sponsoring clinical trial NCT02100514?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.